← Human Trials & Peer-Reviewed Studies
Prognostic utility of mid-regional pro-adrenomedullin and growth differentiation factor 15 in patients undergoing transfemoral transcatheter aortic valve implantation
Plain-language guide to PMID 39453458 (2025): observational study of Adrenomedullin.
Key Facts
- PMID
- 39453458
- Journal
- Clinical research in cardiology : official journal of the German Cardiac Society
- Year
- 2025
- Study type
- Observational Study
- Authors
- Piayda K et al. (14 authors)
- DOI
- 10.1007/s00392-024-02560-w
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Adrenomedullin, published as an observational study.
Risk prediction in patients with severe, symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) remains an unsolved issue.
In addition to classical risk scoring systems, novel circulating biomarkers like mid-regional pro-adrenomedullin (MR-proADM) and growth differentiation factor 15 (GDF-15) may be of value in assessing risk.
Who Took Part
By PubMed's age tags, the people studied were older adults and people over 80, both men and women.
Consecutive patients undergoing elective transfemoral TAVI were included in this prospective observational study.
How the Study Was Run
Baseline information, imaging findings, blood samples, and clinical outcomes were collected.
Blood levels of the classical biomarkers interleukin-6 (IL-6) and high-sensitivity C-reactive peptide (hsCRP) and of the novel biomarkers MR-proADM and GDF-15 were measured and their predictive utility for mortality assessed.
What Was Measured
In addition to classical risk scoring systems, novel circulating biomarkers like mid-regional pro-adrenomedullin (MR-proADM) and growth differentiation factor 15 (GDF-15) may be of value in assessing risk.
Topics PubMed links to this paper include Adrenomedullin, Growth Differentiation Factor 15, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Biomarkers, Protein Precursors and Prognosis.
The authors tagged it with the keywords Mid-regional pro-adrenomedullin, Survival and TAVI.
What This Means in Plain Language
This is an observational study of Adrenomedullin.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Clinical research in cardiology : official journal of the German Cardiac Society), a journal based in Germany.
More context: the Adrenomedullin compound page, all human trials.
Our Notes on the Compound
Adrenomedullin: A 52-amino-acid peptide that widens blood vessels; studied as an infusion in heart, lung and gut conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.